本文由Kalderos CEO Angie Franks撰写，分析了数据碎片化如何导致药品折扣计划低效，并探讨如何通过获取一致性的索赔数据来降低浪费、提高计划完整性和加强药品渠道各利益相关者的协作。
Today’s guest post comes from Angie Franks, CEO at Kalderos.
Angie examines how data fragmentation contributes to inefficiencies in drug discount programs and the broader gross-to-net bubble—the widening difference between a drug’s revenue at list prices and what manufacturers actually receive. Angie outlines how better access to consistent, claims-level data could help reduce waste, improve program integrity, and enhance collaboration among stakeholders in the drug channel.
To learn more, download
Following the Dollars: Why 340B Reform Is a Data-Driven Necessity.
Read on for Angie’s insights.
Read more »
